Cost-Effectiveness Analysis of Pembrolizumab as an Adjuvant Treatment of Resected Stage IIB or IIC Melanoma in the United States

被引：0
|
作者：
Shujing Zhang
Arielle G. Bensimon
Ruifeng Xu
Ruixuan Jiang
Alexandra Greatsinger
Adina Zhang
Mizuho Fukunaga-Kalabis
Clemens Krepler
机构：
[1] Merck & Co.,
[2] Inc.,undefined
[3] Analysis Group,undefined
[4] Inc.,undefined
来源：
Advances in Therapy | 2023年 / 40卷
关键词：
Adjuvant treatment; Cost-effectiveness analysis; Pembrolizumab; Stage IIB–IIC melanoma; US health sector perspective;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：3038 / 3055
页数：17
相关论文
共 50 条
  • [11] Cost-Effectiveness Analysis of Adjuvant Therapy for BRAF-Mutant Resected Stage III Melanoma in Medicare Patients
    Mojtahed, Saam A.
    Boyer, Nicole R.
    Rao, Saieesh A.
    Gajewski, Thomas F.
    Tseng, Jennifer
    Turaga, Kiran K.
    ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (13) : 9039 - 9047
  • [12] Cost-Effectiveness Analysis of Adjuvant Therapy for BRAF-Mutant Resected Stage III Melanoma in Medicare Patients
    Saam A. Mojtahed
    Nicole R. Boyer
    Saieesh A. Rao
    Thomas F. Gajewski
    Jennifer Tseng
    Kiran K. Turaga
    Annals of Surgical Oncology, 2021, 28 : 9039 - 9047
  • [13] NIVOLUMAB-ADJUVANT THERAPY FOR RESECTED STAGE III-IV MELANOMA: A COST-EFFECTIVENESS ANALYSIS FOR SPAIN
    Presa, M.
    Soria, A.
    Oyaguez, I
    Espinosa, E.
    Echave, M.
    Berrocal, A.
    Manzano, J. L.
    Suarez Rodriguez, J.
    Polanco Sanchez, C.
    VALUE IN HEALTH, 2019, 22 : S457 - S457
  • [14] COST-EFFECTIVENESS OF PEMBROLIZUMAB FOR ADVANCED MELANOMA TREATMENT IN PORTUGAL
    Silva Miguel, L.
    Vargas Lopes, F.
    Pinheiro, B.
    Wang, J.
    Xu, R.
    Pellissier, J.
    Laires, P. A.
    VALUE IN HEALTH, 2016, 19 (07) : A729 - A729
  • [15] Adjuvant Pembrolizumab in Resected Stage III Melanoma Reply
    Eggermont, Alexander M. M.
    Robert, Caroline
    Suciu, Stefan
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (06): : 593 - 595
  • [16] UPDATED COST-EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB AS AN ADJUVANT THERAPY FOR RENAL CELL CARCINOMA AFTER NEPHRECTOMY IN THE UNITED STATES
    Xiao, Y.
    Bensimon, A. G.
    Jones, P.
    Gao, E.
    Xu, R.
    Goswami, A.
    Bhattacharya, R.
    VALUE IN HEALTH, 2024, 27 (12) : S122 - S122
  • [17] Adjuvant therapy in stage IIB and IIC melanoma: is sentinel biopsy needed?
    Hindie, Elif
    LANCET, 2022, 400 (10352): : 559 - 559
  • [18] Cost-effectiveness of neoadjuvant pembrolizumab plus chemotherapy with adjuvant pembrolizumab for early-stage non-small cell lung cancer in the United States
    Tian, Wentao
    Niu, Lishui
    Wang, Ziqi
    Lu, Ruoyu
    Xiao, Gang
    Deng, Fuxing
    Tanzhu, Guilong
    Zhou, Rongrong
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [19] Number needed to treat (NNT) with pembrolizumab as an adjuvant therapy in resected patients with high-risk stage II (IIB and IIC) melanoma and its application to cost of preventing an event (COPE) in Mexico
    Wurcel, Victoria
    Rojas Rojas, Monica
    Urrego-Reyes, Juan
    Rivera, Daniela Medrano
    Acevedo, Roberto
    Jiang, Ruixuan
    Jiang, Shan
    Zhang, Shujing
    Caparros, Alfredo
    Krepler, Clemens
    Fukunaga-Kalabis, Mizuho
    Younan, Nadine D.
    Alexander, Deepak
    Hughes, Robert
    Weston, Georgie
    JOURNAL OF MEDICAL ECONOMICS, 2025, 28 (01) : 346 - 353
  • [20] Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
    Eggermont, Alexander M. M.
    Blank, Christian U.
    Mandala, Mario
    Long, Georgina, V
    Atkinson, Victoria
    Dalle, Stephane
    Haydon, Andrew
    Lichinitser, Mikhail
    Khattak, Adnan
    Carlino, Matteo S.
    Sandhu, Shahneen
    Larkin, James
    Puig, Susana
    Ascierto, Paolo A.
    Rutkowski, Piotr
    Schadendorf, Dirk
    Koornstra, Rutger
    Hernandez-Aya, Leonel
    Maio, Michele
    van den Eertwegh, Alfonsus J. M.
    Grob, Jean-Jacques
    Gutzmer, Ralf
    Jamal, Rahima
    Lorigan, Paul
    Ibrahim, Nageatte
    Marreaud, Sandrine
    van Akkooi, Alexander C. J.
    Suciu, Stefan
    Robert, Caroline
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (19): : 1789 - 1801
12345